ISRCTN50580483已完成3 期
A randomised controlled phase III trial of patients with non-metastatic Ewing sarcoma treated with either a prolonged treatment or a shorter dose-intense treatment and the effect on probability of survival
Italian Sarcoma Group (Italy)0 个研究点目标入组 220 人开始时间: 2010年4月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with non-metastatic Ewing sarcoma
- •2. Aged less than 41 years, either sex
- •3. No previous treatment for the disease
- •4. Informed consent
排除标准
- •1. Metastatic Ewing sarcoma
- •2. Medical contraindications to the protocol drugs
研究者
相似试验
已完成
3 期
A Phase III randomized controlled clinical trial of CARBOPLATIN and PACLITAXEL(OR GEMCITABINE) alone or in combination with BEVACIZUMAB (NSC #704865, IND #7921) followed by BEVACIZUMAB and secondary cytoredutive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer.PLATINUM-SENSITIVE, RECURRENT OVARIAN, PERITONEAL PRIMARY AND FALLOPIAN TUBE CANCERJPRN-UMIN000003682Gynecologic Oncology Group1,050
招募中
3 期
Phase III randomised trial evaluating chemotherapy early treatment intensification with temozolomide in adults present with a glioblastoma2022-500451-23-00Centre Oscar Lambret400
进行中（未招募）
不适用
Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic non-small-cell lung cnacer patients.Treatment in locally advanced or metastatic non-small-lung cancer.EUCTR2004-001904-10-EEPierre Fabre Medicament represented by IRPF350
进行中（未招募）
不适用
Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic non-small-cell lung cnacer patients.EUCTR2004-001904-10-ATPierre Fabre Médicament represented by IRPF350
进行中（未招募）
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2015-005731-41-IEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990